» Articles » PMID: 38361941

Forces at Play: Exploring Factors Affecting the Cancer Metastasis

Overview
Journal Front Immunol
Date 2024 Feb 16
PMID 38361941
Authors
Affiliations
Soon will be listed here.
Abstract

Metastatic disease, a leading and lethal indication of deaths associated with tumors, results from the dissemination of metastatic tumor cells from the site of primary origin to a distant organ. Dispersion of metastatic cells during the development of tumors at distant organs leads to failure to comply with conventional treatments, ultimately instigating abrupt tissue homeostasis and organ failure. Increasing evidence indicates that the tumor microenvironment (TME) is a crucial factor in cancer progression and the process of metastatic tumor development at secondary sites. TME comprises several factors contributing to the initiation and progression of the metastatic cascade. Among these, various cell types in TME, such as mesenchymal stem cells (MSCs), lymphatic endothelial cells (LECs), cancer-associated fibroblasts (CAFs), myeloid-derived suppressor cells (MDSCs), T cells, and tumor-associated macrophages (TAMs), are significant players participating in cancer metastasis. Besides, various other factors, such as extracellular matrix (ECM), gut microbiota, circadian rhythm, and hypoxia, also shape the TME and impact the metastatic cascade. A thorough understanding of the functions of TME components in tumor progression and metastasis is necessary to discover new therapeutic strategies targeting the metastatic tumor cells and TME. Therefore, we reviewed these pivotal TME components and highlighted the background knowledge on how these cell types and disrupted components of TME influence the metastatic cascade and establish the premetastatic niche. This review will help researchers identify these altered components' molecular patterns and design an optimized, targeted therapy to treat solid tumors and restrict metastatic cascade.

Citing Articles

Circadian rhythms and cancer: implications for timing in therapy.

El-Tanani M, Rabbani S, Ali A, Alfaouri I, Al Nsairat H, Al-Ani I Discov Oncol. 2024; 15(1):767.

PMID: 39692981 PMC: 11655929. DOI: 10.1007/s12672-024-01643-4.


Circadian rhythms and breast cancer: unraveling the biological clock's role in tumor microenvironment and ageing.

Yan Y, Su L, Huang S, He Q, Lu J, Luo H Front Immunol. 2024; 15:1444426.

PMID: 39139571 PMC: 11319165. DOI: 10.3389/fimmu.2024.1444426.


Breast Cancer: Extracellular Matrix and Microbiome Interactions.

Herrera-Quintana L, Vazquez-Lorente H, Plaza-Diaz J Int J Mol Sci. 2024; 25(13).

PMID: 39000333 PMC: 11242809. DOI: 10.3390/ijms25137226.

References
1.
Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

2.
Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

3.
Liu Y, Baba Y, Ishimoto T, Gu X, Zhang J, Nomoto D . Gut microbiome in gastrointestinal cancer: a friend or foe?. Int J Biol Sci. 2022; 18(10):4101-4117. PMC: 9274484. DOI: 10.7150/ijbs.69331. View

4.
Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

5.
Hua H, Li M, Luo T, Yin Y, Jiang Y . Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011; 68(23):3853-68. PMC: 11114831. DOI: 10.1007/s00018-011-0763-x. View